Loading
journalsJournal
Breast cancer research
Breast Cancer Research is an open access journal for laboratory, translational and clinical breast cancer science, read by breast cancer researchers and specialist clinicians.
Also called: Breast cancer research : BCRBreast Cancer ResearchBCRBreast Cancer Res
Overview
Breast Cancer Research was launched in 1999 by BioMed Central in London and is published by BMC, part of Springer Nature. As its title indicates, it is devoted to research on breast cancer, from laboratory science to clinical studies, and its DOAJ and NLM records list it as an English journal published from London. It is fully open access and listed in DOAJ with CC BY and CC BY-NC-ND licences, an article processing charge and anonymous peer review, with open access content from 2000. Indexed in MEDLINE.
Publisher
BMC (Springer Nature)
Scope
breast cancer
Access model
open access
Founded
1999
ISSN
1465-5411
observational202330 citations
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms
This is the population-based prevalence for the two label thresholds in early TNBC, and it shows the KEYNOTE-355 CPS 10 gate would admit only about a quarter of unselected patients.
translational2008208 citations
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas
Functional RB1 loss is part of basal-like biology, which explains why CDK4/6 inhibitors have not worked in TNBC and why the cell-cycle vulnerability there lies downstream of RB.
Robert Šeparović
Representative of University Hospital for Tumors, Sestre milosrdnice University Hospital Centre to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
Robert Šeparović represents University Hospital for Tumors, Sestre milosrdnice University Hospital Centre in the Organisation of European Cancer Institutes, which lists the centre among its members in Croatia.
Samantha Oakes
CEO
Cancer research managementBreast and prostate cancer biologyClinical trials operations
Cancer biologist turned research executive who serves as CEO of the ANZUP Cancer Trials Group.
Senthil K. Muthuswamy
Director, Center for Cancer Research, National Cancer Institute
Cancer cell biologyOrganoid modelsBreast and pancreatic cancer
Cancer biologist who directs the National Cancer Institute's Center for Cancer Research, the large intramural research programme in Bethesda.
observationalBreast Cancer Research 202330 citations
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms
This is the population-based prevalence for the two label thresholds in early TNBC, and it shows the KEYNOTE-355 CPS 10 gate would admit only about a quarter of unselected patients.
translationalBreast Cancer Research 2008208 citations
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas
Functional RB1 loss is part of basal-like biology, which explains why CDK4/6 inhibitors have not worked in TNBC and why the cell-cycle vulnerability there lies downstream of RB.
Similar pages
- JournalThe breast journal
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, PubMed & Europe PMC, HER2-positive breast cancer.
- JournalBreast cancer
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, PubMed & Europe PMC, HER2-positive breast cancer.
- JournalJournal of mammary gland biology and neoplasia
Shares Ductal carcinoma in situ (DCIS), PubMed & Europe PMC, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- JournalJournal of breast imaging
Shares Ductal carcinoma in situ (DCIS), PubMed & Europe PMC, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- JournalThe Breast
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, PubMed & Europe PMC, HER2-positive breast cancer.
- JournalClinical breast cancer
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, PubMed & Europe PMC, HER2-positive breast cancer.
- TermBreast implant-associated anaplastic large cell lymphoma
Shares Male breast cancer, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- TermHow ER and PR are scored on a breast report (Allred score, H score, and why PR is not a UK core item)
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
cancers
collections
people
key papers
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithmsThe functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas